Skip to main content

Table 1 Baseline Characteristics

From: Outcomes of Cardiac Resynchronization Therapy in Patients with Hypothyroidism and Heart Failure

Variable All (n = 1316) Euthyroidism (n = 966) Hypothyroidism (n = 350) P Value
Age, y 69.8 ± 12.2 69.3 ± 12.4 71.2 ± 11.2 0.01
Female 289 (22.0) 184 (19.0) 105 (30.0) < 0.001
CRT-D 1181 (89.7) 867 (89.7) 314 (90.0) 0.87
Primary prevention 979 (82.9) 749 (86.5) 230 (73.0) < 0.001
Hypertension 539 (41.0) 398 (41.2) 141 (40.4) 0.81
Diabetes mellitus 398 (30.2) 297 (30.7) 101 (28.9) 0.54
Chronic kidney disease 357 (27.1) 248 (25.7) 109 (31.2) 0.04
Hyperlipidemia 600 (45.7) 442 (45.7) 158 (45.4) 0.92
Atrial fibrillation history 599 (44.5) 430 (44.5) 169 (48.4) 0.20
ICM 632 (48.0) 462 (47.8) 170 (48.7) 0.77
LBBB 644 (40.1) 491 (52.2) 153 (44.5) 0.02
QRS duration, ms 170.2 ± 28.5 169.5 ± 28.2 172.1 ± 29.4 0.16
NYHA functional class, 1–4 2.8 ± 0.6 2.8 ± 0.6 2.9 ± 0.5 0.64
 3–4 892 644 (69.7) 248 (73.6)  
 2 349 264 (28.6) 85 (25.2)  
 1 20 16 (1.7) 4 (1.2)  
LVEF, % 24.3 ± 6.5 24.2 ± 6.6 24.4 ± 6.6 0.62
TRT 254 (19.3) 0 (0) 254 (72.9) < 0.001
Amiodarone 232 (17.6) 135 (14.0) 97 (27.9) < 0.001
Statin 705 (53.6) 529 (54.7) 176 (50.4) 0.17
Digoxin 539 (41.0) 391 (40.4) 148 (42.4) 0.52
β-blocker 1156 (87.8) 853 (88.2) 303 (86.8) 0.50
ACEI/ARB 1054 (80.1) 781 (80.8) 273 (78.2) 0.31
Aldactone 391 (29.7) 288 (29.8) 103 (29.5) 0.93
Furosemide 886 (67.3) 640 (66.2) 246 (70.5) 0.14
  1. Values are count (%) or mean ± SD
  2. Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CRT-D cardiac resynchronization therapy-defibrillator, ICM ischemic cardiomyopathy, LBBB left bundle branch block, LVEF left ventricular ejection fraction, NYHA New York Heart Association, TRT thyroid replacement therapy